Results 111 to 120 of about 3,191 (210)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

Therapeutics and Clinical Risk Management, 2016
Mary Lou Affronti,1–3 Sarah Woodring,1,2 Katherine B Peters,1,4 James E Herndon II,5 Frances McSherry,5 Patrick N Healy,5 Annick Desjardins,1,4 James J Vredenburgh,6 Henry S Friedman1,2 1The Preston Robert Tisch Brain Tumor Center at Duke ...
Affronti ML, Woodring S, Peters KB, Herndon II JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS   +8 more
doaj  

sj-docx-6-hpx-10.1177_00185787241231739 – Supplemental material for Trial Sequential Analysis and Meta-Analysis of Olanzapine in Pediatric Patients for Chemotherapy-Induced Nausea and Vomiting (CINV) [PDF]

Supplemental material, sj-docx-6-hpx-10.1177_00185787241231739 for Trial Sequential Analysis and Meta-Analysis of Olanzapine in Pediatric Patients for Chemotherapy-Induced Nausea and Vomiting (CINV) by Alok Singh, Dhyuti Gupta, Pankaj Kumar Kannauje and ...
Pankaj Kumar Kannauje (17983114), Dhyuti Gupta (16508682), Amit Kumar Agrawal (17983117), Alok Singh (1871617)   +3 more
core   +1 more source

Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV) [PDF]

, 2017
Noha Rashad,1 Omar Abdel-Rahman2 1Medical Oncology Department, Maadi Armed Forces Hospital, 2Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt Abstract: Rolapitant is a highly selective neurokinin-1 receptor ...
Rashad N, Abdel-Rahman O
core  

Impact of Evolving Antiemetic Prophylaxis on Chemotherapy-Induced Nausea and Vomiting (CINV): A Five-Year Comparative Study in Sichuan, China (2018-2023). [PDF]

Cancer Manag Res
Xiong W, Zhang W, Zhao Q, Zheng Y, Xie K, Miao J, Chen L, Li T, Cao W, Zhu, Huang M, Li C, Wang Y, Gui Y, Li Q, Cao C, Yang Y, Du C, Gao Y, Zhou Y, Zhang H, Le X, Chen P, Jiang M, Li P, Yang J, Wang Y, Zhu J, He L.   +28 more
europepmc   +1 more source

Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study. [PDF]

Clin Pharmacol
Muasya PK, Yadesa TM, Isiiko J, Kyomya J, Oenga J, Amina A, Nimusiima G, Joel S, Tumwebaza JM, Makuza KR.   +9 more
europepmc   +1 more source

What do cancer patients discuss online regarding CINV management? A social media-based topic modeling study. [PDF]

Front Oncol
Jiang H, Shen W, Zhou M, Lyu Y, Meng M, Yang D, Li X, Zhang B, Hao Y.   +8 more
europepmc   +1 more source

Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). [PDF]

Cancer Chemother Pharmacol
Iimura Y, Iihara H, Aoyama T, Hayashi T, Ishibashi M, Sasuga C, Furukawa N, Anzai E, Ijichi Y, Kuroda S.   +9 more
europepmc   +1 more source

Acupuncture Therapies for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer: Protocol for a Systematic Review and Network Meta-Analysis. [PDF]

JMIR Res Protoc
Luo Y, Bian Z, Wang Q, Lei T, Zhao H.
europepmc   +1 more source

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]

Cancer Manag Res
Maeda K, Kawada K, Hayashi T, Koyama S, Ishida T, Yoshioka T, Fukuda H, Horikawa I, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Ishizawa K.   +13 more
europepmc   +1 more source

Awareness of chemotherapy-induced nausea and vomiting and adherence to guidelines: results of a multinational and multicenter survey, part of the THRIVE program. [PDF]

Support Care Cancer
Caponero R, Enrico D, Giudice F, Ayoub JP, Lapointe N.   +4 more
europepmc   +1 more source